Related Experiment Video
Updated: Jun 16, 2026
11:16
Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells
Published on: February 15, 2019
The future of non-human primate use in mAb development
Kathryn L Chapman1, Nick Pullen, Laura Andrews
1National Centre for the Replacement, Refinement and Reduction of Animals in Research, 20 Park Crescent, London W1B1AL, UK. kathryn.chapman@nc3rs.org.uk
Drug Discovery Today
|January 26, 2010
Summary
The use of non-human primates (NHPs) in monoclonal antibody (mAb) development may increase, but a science-based approach can minimize this. This article proposes a framework to reduce NHP use while supporting innovation.
Area of Science:
- Biotechnology
- Pharmacology
- Animal Research Ethics
Background:
- Monoclonal antibody (mAb) development is increasing.
- Non-human primate (NHP) use in mAb development is predicted to rise significantly.
- Concerns exist regarding the ethical implications and necessity of increased NHP utilization.
Purpose of the Study:
- To review current and projected NHP use in mAb development.
- To propose a framework for minimizing NHP use in this field.
- To ensure continued scientific rigor and innovation alongside reduced animal use.
Main Methods:
- Surveys of current NHP usage in mAb development.
- Analysis of expert opinions on NHP use.
- Review of existing scientific literature and experience.
- Development of a proposed framework for NHP reduction.
Main Results:
- NHP use in mAb development is projected to increase.
- Opportunities exist for a rigorous, science-based approach to mitigate this increase.
- A framework is proposed to balance NHP reduction with scientific advancement.
Conclusions:
- Strategic planning and a science-led approach can significantly minimize NHP use in mAb development.
- The proposed framework supports ethical considerations and maintains scientific integrity.
- Future NHP use can be optimized through careful consideration and innovative strategies.
